Phase I-II Trial of Gemcitabine-Based First-Line Chemotherapies for Small Cell Lung Cancer in Elderly Patients with Performance Status 0-2: The G-Step Trial  by Gridelli, Cesare et al.
ORIGINAL ARTICLE
Phase I–II Trial of Gemcitabine-Based First-Line
Chemotherapies for Small Cell Lung Cancer in Elderly
Patients with Performance Status 0–2
The G-Step Trial
Cesare Gridelli, MD,* Ciro Gallo, MD,† Alessandro Morabito, MD,‡§
Rosario Vincenzo Iaffaioli, MD, Adolfo Favaretto, MD,¶ Luciano Isa, MD,# Santi Barbera, MD,**
Teresa Gamucci, MD,†† Anna Ceribelli, MD,‡‡ Virginio Filipazzi, MD,§§ Paolo Maione, MD,*
Antonio Rossi, MD,* Emiddio Barletta, MD, Simona Signoriello, MD,† Ermelinda De Maio, MD,‡
Maria Carmela Piccirillo, MD,‡ Massimo Di Maio, MD,‡ Gaetano Rocco, MD,§
Aldo Vecchione, MD,‡ and Francesco Perrone, MD‡; on behalf of the G-STEP Investigators
Introduction: Treatment of elderly patients with small cell lung
cancer (SCLC) is based on scanty evidence.
Methods: Patients with extensive SCLC, age 70 years, and
performance status 0–2 were eligible for a study looking for optimal
two-drug combination of gemcitabine (Gem) with vinorelbine (Vin),
etoposide (Eto), cisplatin (Cis), or carboplatin (Car). Gemcitabine
dose was the same (1000 mg/m2, days 1–8) in all combinations. A
two-stage minimax flexible design for response was applied to
GemVin combination (Vin 25 mg/m2, days 1–8). For GemCar,
GemCis, GemEto, a phase I–II Bayesian design was applied, look-
ing for the optimal dose of the partner drugs. Objective response rate
60% and unacceptable toxicity 25% were required to define a
combination worthy of further studies.
Results: Median age of 78 eligible patients was 74 years. GemVin
produced a 36.7% objective response rate. GemEto and GemCis
arms were found not sufficiently active. GemCar produced 16
responses (14 with area under the curve [AUC] 3.5 and 2 with AUC
4.0) in 26 patients (61.5%) and 6 cases of unacceptable toxicity (3
at each Car dose).
Conclusions: In elderly patients with extensive SCLC, GemVin,
GemEto, and GemCis are not enough active and do not merit further
studies. Gem plus Car might deserve further attention.
Key Words: Elderly, SCLC, Gemcitabine, Vinorelbine, Etoposide,
Platinum compounds.
(J Thorac Oncol. 2012;7: 233–242)
Small cell lung cancer (SCLC) represents about 15% of alllung cancers.1 Chemotherapy with cisplatin (Cis) or car-
boplatin (Car) and etoposide (Eto) is the standard regimen for
patients with extensive disease with 60 to 80% response rates
and a median overall survival (OS) of 8 to 13 months.2
Approximately 30% of SCLC patients are older than 70
years at diagnosis.3 Little knowledge exists about the efficacy
of chemotherapy in elderly patients, because they are often
excluded from prospective clinical trials.4–6 Retrospective
studies suggest that elderly patients may benefit from chemo-
therapy as younger patients, but with higher risk of toxic-
ity.7–11 Consequently, the optimal treatment of these patients
is still controversial.12
Gemcitabine (Gem) is well tolerated in elderly patients,
and there was evidence of activity in SCLC, both as single-
agent and in combination. In particular, two phase II studies
evaluated Gem as single agent, reporting a response rate of
27% and a median survival of 12 months in the treatment of
chemo-naive SCLC patients13 and a response rate of 13% in
pretreated patients.14 Gem has also been studied in a doublet
with Eto15 and in triplets with Cis and Eto,16,17 showing the
feasibility of these combinations and a reassuring activity rate.
On these bases, we planned a four-arm, phase I–II study
to evaluate the feasibility of four Gem-based doublets as a
first-line chemotherapy for elderly patients with extensive
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SCLC (Gem-based Small-cell lung cancer Treatment in El-
derly Patients, G-STEP). The four drugs to be combined with
Gem were vinorelbine (Vin; GemVin arm), Eto (GemEto
arm), Cis (GemCis arm), and Car (GemCar arm). Eto, Cis,
and Car are commonly used in the treatment of SCLC.2 Vin
was chosen, because it was well tolerated and had shown
activity against SCLC.18,19
PATIENTS AND METHODS
G-STEP was a multicenter, open-label, four-arm, phase
I–II study. Ethics Committees of each participating institution
approved the study protocol. All patients provided written
informed consent.
Patients
Inclusion criteria were age 70, SCLC diagnosis con-
firmed histologically or cytologically, extensive disease stage
according to Veterans Administration Lung Cancer Group
classification, 1 measurable lesion, Eastern Cooperative
Oncology Group performance status (PS) 0–2, and no previ-
ous chemotherapy. Patients with asymptomatic brain metas-
tases were eligible; previous radiotherapy was allowed if
completed at least 4 weeks before study entry, with measur-
able disease in a site that had never been irradiated. Patients
were excluded if they had a history of prior invasive malig-
nancy or inadequate bone marrow (neutrophils 2000/mm3,
platelets 100,000/mm3, hemoglobin 10 g/dl), hepatic (al-
anine aminotransferase, aspartate transaminase2.5 upper
normal limit (UNL), and bilirubin 1.5  UNL in the
absence of liver metastases, or alanine aminotransferase and
aspartate transaminase 5  UNL and bilirubin 3  UNL
in the presence of liver metastases), or renal function (serum
creatinine 1.5  UNL).
Treatments
All the drugs were given intravenously. Dose of Gem
was 1000 mg/m2 on days 1 and 8, every 3 weeks, in all arms;
Gem was administered as 30-minute infusion, before the
partner drugs. In the GemVin arm, Vin was given at fixed
dose (25 mg/m2) on days 1 and 8. In the other arms, three
doses were investigated for each partner drug: for Eto 60, 70,
and 80 mg/m2, days 1 to 3; for Cis 50, 60, and 70 mg/m2, day
1; for Car AUC 3.5, 4, and 4.5, according to Calvert formula,
day 1.20 For all doublets, cycles were planned every 21 days.
Hydration and antiemetic treatments were done according to
clinical practice of participating centers.
Minimum requirements to receive chemotherapy on days
1 and 8 were neutrophils2000/mm3, platelets100,000/mm3,
Hb 8 g/dl, and absence of nonhematological grade 2
toxicity (excluding alopecia). If such conditions were not met
at day 8, drug administration was omitted; if they were not
met at day 1, treatment was delayed for 1 week, for a
maximum of 2 weeks. Subsequently, chemotherapy had to be
interrupted. Dose reductions were not planned. Blood cell
counts were monitored weekly. If day 8 administration was
not possible because of neutropenia, granulocyte-colony
stimulating factor was administered from days 4 to 6 of the
following cycles. In the case of grade 4 neutropenia, granu-
locyte-colony stimulating factor was given and could be
administered as prophylaxis in the subsequent cycles. The use
of erythropoietin was allowed according to registration. Pal-
liative radiotherapy was permitted if required.
Patients who achieved an objective response (OR) after
three cycles continued the same treatment for further three
cycles, up to a maximum of six cycles. Patients who achieved
stable disease received further three cycles or switched to a
second-line chemotherapy according to investigator judg-
ment. Patients with progressive disease stopped treatment and
could receive a second-line chemotherapy.
Activity and Safety Assessment
Planned activity and safety assessments were the same
across all arms. At baseline, patients underwent complete
history and physical examination; routine hematology and
biochemistry; electrocardiogram; chest x-ray; computed to-
mography (CT) scan of the head, chest, and abdomen; radio-
nuclide bone scanning; and x-ray or CT scan of all areas of
abnormal uptake on bone scanning. Other examinations could
be performed based on investigator judgment.
Response was assessed after three and six cycles by
repeating chest x-ray, chest and abdomen CT scan, and other
examinations eventually used at baseline. Response was de-
fined according to Response Evaluation Criteria in Solid
Tumors.21 There was no central or independent verification of
response. Patients were classified as nonresponders if they
could not be restaged because of treatment failure, according
to investigators judgment. Other reasons (such as death or
disability due to accidental circumstances, death before the
start of treatment), clearly not related to the study treatment,
induced exclusion from the statistical analysis.
Routine hematology, biochemistry, urinalysis, and physi-
cal examination were performed every 3 weeks, before the
administration of chemotherapy, and hematology was also re-
peated before chemotherapy on day 8 of each cycle. Electrocar-
diogram was repeated after three and six cycles. Toxicities were
assessed using the National Cancer Institute Common Toxicity
Criteria (version 2.0). Unacceptable toxicity was defined as the
occurrence of at least one of the following events: febrile
neutropenia, grade 3 neutropenic infection or thrombocytope-
nia or anemia or stomatitis or diarrhea or constipation, grade 4
vomiting, grade 2 any other organ toxicity (excluding alope-
cia), any toxicity inducing deterioration of general condition,
and precluding restaging after three cycles.
A geriatric assessment was planned at baseline. The
Charlson score22 was used to summarize comorbidities; how-
ever, because many diseases were excluded by eligibility crite-
ria, higher scores were rarely attained, and just three categories
were used in the analysis (0, 1, and 2). As for activities of daily
living (ADL), patients were classified as not impaired at all or
with at least one activity impaired.23 Even Instrumental ADL
(IADL) scores were grouped in two categories, independent or
not independent in more than 50% of items.24,25
The QLQ-C30 and LC13 European Organization for
Research and Treatment of Cancer questionnaires were
used for quality of life (QoL) assessment.26,27 In this
report, only baseline items 29 and 30 of QLQ-C30 are
considered, categorized as low (worse) or high (better) as
per a cutoff of 67%.25
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Statistical Design
Two different statistical designs were applied, one for
GemVin arm and another for the other doublets, because of
the different level of evidence about safety in elderly patients.
For the GemVin arm, adequate safety information was
already available28; therefore, a dose-finding step was not
required. A two-stage minimax flexible design was applied,
with OR as endpoint.29 Design parameters p0 (minimal ac-
ceptable proportion of ORs), p1 (desirable proportion of
ORs),  and  were set equal to 0.40, 0.60, 0.10, and 0.10,
respectively. We chose a flexible approach with the sample
size of the first stage ranging from 23 to 30 patients and that
of the second stage ranging from 37 to 44 patients. With 30
patients enrolled at the first stage, 13 responses were required
to proceed to the second stage.
For GemEto, GemCis, and GemCar combinations, no
adequate safety information was available, and a preliminary
dose-finding phase was needed. Therefore, a hybrid phase I/II
design was applied to look for the optimal dose, based on
safety and efficacy monitoring.30 The main characteristics of
the Thall and Russell design are (1) both dose-finding and
activity evaluation at the selected dose are performed within
the same framework; (2) both safety and activity are contem-
porarily considered for outcome assessment; (3) a dose-
response proportional odds regression model is assumed with
three possible ordered outcomes for each dose (“not active,”
“active and not toxic,” and “toxic”); (4) probabilities of each
outcome are updated as information accumulates, according
to a Bayesian approach; (5) given the accumulated knowl-
edge up to the current cohort, doses are escalated or de-
escalated, or the trial is stopped, if probability of either of the
undesirable outcomes is strong enough, or more subjects are
enrolled in the acceptable dose until a predefined sample size
is attained. The software for trial design and monitoring was
kindly supplied by Dr. Thall.
Treatment was defined as “not active” if OR was not
achieved by three cycles of treatment. Patients who could not
be restaged because of treatment failure according to the
investigator’s judgment were considered not responders. Treat-
ment was defined as “toxic” in presence of 1 unacceptable
toxicity in the first three cycles, irrespective of activity. If neither
of the previous outcomes occurred, treatment was defined “ac-
tive and not toxic” at the acceptable dose.
The parameters of desirable activity and acceptable
toxicity were predefined. In this study, the desirable pro-
portion of ORs was set equal to 60% (as in GemVin arm)
and the maximum acceptable percentage of unacceptable
toxicity equal to 25% (i.e., a treatment “active and not toxic”
would result from an OR rate 60%, with a severe toxicity
rate 25%).
Operating characteristics of the design were obtained
via simulation. In this study, 130,000 simulations were per-
formed to investigate 12 possible clinical scenarios encom-
passing the range of expected dose effects. Finally, a poste-
rior probability threshold of 0.90 was chosen for both activity
and toxicity, that is, probability that a dose would be consid-
ered inactive (or toxic) to escalate (or to de-escalate) had to
be at least 90%. Cohort size was set equal to 2 and sample
size equal to 40. With these parameters, the probability of
an inconclusive result was less than 0.06 with all clinical
scenarios.
Although, in principle, the four combinations were
multiple arms of a randomized trial, the allocation of patients
to treatment was driven by the dose-finding rules and the need
of waiting for the outcomes of the current cohorts. Therefore,
randomization was performed at the very beginning and as
often as it was possible, but actually, in most cases, patients
were enrolled consecutively to complete cohorts of two
according to the randomized order and were assigned to the
GemVin arm, while waiting for outcome in the current
cohorts.31 Such scheme was applied centrally at the coordi-
nating center (NCI Napoli).
Secondary endpoints were OS, progression-free sur-
vival (PFS), and QoL. QoL results are not reported in this
FIGURE 1. Study flow according
to CONSORT statement.
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article. An exploratory analysis of prognostic factors on OS
was also performed by means of a Cox regression model,
stratified by treatment arm.
RESULTS
From May 2000 to September 2005, 83 patients were
enrolled (Figure 1). Five patients resulted not eligible because
of age (n  1), refusal before third cycle (n  3), and limited
stage (n  1). Baseline characteristics of the 78 eligible
patients are shown in Table 1. There were no statistically
significant differences among arms. Median age was 74
years, 88% of the patients were male, and 90% had a good
PS. Most patients had multiple comorbidities. The Charlson
score was 2 in 26.9%. Number of comorbidities and the
Charlson score tended to be higher in the GemEto arm.
Baseline assessment of ADL and IADL were missing for 8%
and 6% of patients, respectively. Seventeen percent of pa-
tients had some ADL dependency, and 40% was dependent in
more than 50% of IADL. Baseline global QoL score was high
(67%) in 20.5%.
Overall, of 78 eligible patients, with a median fol-
low-up of 83 weeks, 73 progressed and 66 died, with a
median PFS of 21 weeks (95% CI 18–24) and a median OS
of 34 weeks (95% CI 26–41) (Figure 2).
TABLE 1. Baseline Characteristics of Eligible Patients
Variable
Total
(n  78)
Gem 
Vinorelbine
(n  30)
Gem 
Etoposide
(n  10)
Gem 
Cisplatin
(n  12)
Gem 
Carboplatin
(n  26)
Exact
p Value
Age (yr), n (%)
75 45 (57.7) 17 (56.7) 7 (70.0) 5 (41.7) 16 (61.5) 0.43
75 and 80 24 (30.8) 10 (33.3) 3 (30.0) 3 (25) 8 (30.8)
80 9 (11.5) 3 (10) — 4 (33.3) 2 (7.7)
Median (range) 74 (70–83) 74 (70–82) 73 (70–78) 76 (71–83) 73 (70–82)
Gender, n (%)
Males 69 (88.5) 27 (90.0) 9 (90.0) 8 (66.7) 25 (96.2) 0.07
Females 9 (11.5) 3 (10.0) 1 (10.0) 4 (33.3) 1 (3.8)
Performance status, n (%)
0–1 70 (89.7) 28 (93.3) 9 (90.0) 10 (83.3) 23 (88.5) 0.86
2 8 (10.3) 2 (6.7) 1 (10.0) 2 (16.7) 3 (11.5)
Previous radiotherapy, n (%)
No 77 (98.7) 29 (96.7) 10 (100.0) 12 (100) 26 (100) 1.00
Yes 1 (1.3) 1 (3.3) — — —
Brain metastasis, n (%)
Absent 71 (91.0) 26 (86.7) 9 (90.0) 11 (91.7) 25 (96.2) 0.77
Present 7 (9.0) 4 (13.3) 1 (10.0) 1 (8.3) 1 (3.8)
Comorbidities, n (%)
None 9 (11.6) 2 (6.7) — 3 (25.0) 4 (15.4) 0.14
1 11 (14.1) 6 (20.0) 1 (10.0) 1 (8.3) 3 (11.6)
2 20 (25.6) 8 (26.7) 2 (20.0) 1 (8.3) 9 (34.6)
3 12 (15.4) 7 (23.3) — 3 (25.0) 2 (7.7)
4 or more 26 (33.3) 7 (23.3) 7 (70.0) 4 (33.3) 8 (30.8)
Charlson score, n (%)
0 25 (32.1) 11 (36.7) — 6 (50.0) 8 (30.8) 0.054
1 32 (41.0) 15 (50.0) 4 (40.0) 3 (25.0) 10 (38.5)
2 or more 21 (26.9) 4 (13.3) 6 (60.0) 3 (25.0) 8 (30.8)
ADL score, n (%)
Not available 6 (7.7) 2 (6.7) — 1 (8.3) 3 (11.5) 0.81
1 13 (16.7) 4 (13.3) 2 (20.0) 1 (8.3) 6 (23.1)
No impairment 59 (75.6) 24 (80.0) 8 (80.0) 10 (83.3) 17 (65.4)
IADL independency, n (%)
Not available 5 (6.4) 1 (3.3) — 1 (8.3) 3 (11.5) 0.82
50% 31 (39.7) 13 (43.3) 3 (30.0) 5 (41.7) 10 (38.5)
50% 42 (53.9) 16 (53.3) 7 (70.0) 6 (50.0) 13 (50.0)
Overall QoL score, n (%)
Not available 13 (16.7) 5 (16.7) — 3 (25.0) 5 (19.2) 0.49
Low/worse (67%) 49 (62.8) 18 (60.0) 6 (60.0) 7 (58.3) 18 (69.2)
High/better (67%) 16 (20.5) 7 (23.3) 4 (40.0) 2 (16.7) 3 (11.5)
ADL, activities of daily living; IADL, instrumental ADL; QoL, quality of life.
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TABLE 2. Outcome of Treatment
n
Activity and Safety Time-to-Event Efficacy
Treatment Outcome Response Rate
Patients
at Risk
(n)
Progression-Free
Survival Overall Survival
Objective
Response
Severe
Toxicity
% (95%
Exact CI)
Events
(n)
Median
(95% CI), wk
Events
(n)
Median
(95% CI), wk
Gem  vinorelbine 30 11 4 36.7 (19.9–56.1) 30 27 15 (11–21) 25 23 (19–40)
Gem 
Etoposide (dose 60) 6 1 3 10.0 (0.2–44.5) 10 10 15 (6–31) 9 40 (12–49)
Etoposide (dose 70) 2 0 1
Etoposide (dose 80) 2 0 1
Gem 
Cisplatin (dose 50) 4 0 1 16.7 (2.1–48.4) 12 11 17 (9–21) 11 22 (15–41)
Cisplatin (dose 60) 6 1 4
Cisplatin (dose 70) 2 1 0
Gem 
Carboplatin (dose AUC 3.5) 22 14 3 61.5 (40.6–79.8) 26 25 25 (22–28) 21 37 (34–56)
Carboplatin (dose AUC 4) 4 2 3
Carboplatin (dose AUC 4.5) —
CI, confidence interval.
FIGURE 2. Curves of overall survival (A, whole series of eligible patients; C, scattered by chemotherapy arm) and progres-
sion-free survival (B, whole series of eligible patients; D, scattered by chemotherapy arm). Black, gemcitabine  vinorelbine;
blue, gemcitabine  carboplatin; red, gemcitabine  cisplatin; green, gemcitabine  etoposide. Dotted line represents 95%
confidence intervals.
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Gemcitabine  Vinorelbine Arm
Thirty patients were enrolled in this arm. OR was
reached in 11 patients (36.7%). Therefore, the enrolment was
closed after the first stage because the required number of
responses was not reached. Median survival was 23 weeks,
and median PFS was 15 weeks (Table 2 and Figure 2).
Toxicity was mild (Table 3).
Gemcitabine  Etoposide Arm
This arm was closed early, because the highest dose of
Eto (80 mg/m2) was considered not active (Figure 3). Ten
patients were treated, six at dose level 1, two at dose level 2,
and two at dose level 3. There was one OR at dose level 1,
whereas unacceptable toxicity occurred in five cases (three at
dose level 1 and one at the other dose level). Overall OR rate
was 10.0%, median survival was 40 weeks, and median PFS
was 15 weeks (Table 2 and Figure 2). There was one toxic
death, at dose level 2, because of acute heart failure after
the first cycle, in a patient without significant cardiovas-
cular comorbidities. Grade 4 neutropenia was reported in
two patients and grade 4 febrile neutropenia in one patient
(Table 3).
Gemcitabine  Cisplatin Arm
This arm was closed early, because the highest dose of
Cis (70 mg/m2) was considered not active (Figure 3). Twelve
patients were treated, four at dose level 1, six at dose level 2,
and two at dose level 3. There were two ORs (one each at
dose levels 2 and 3), while unacceptable toxicity occurred in
five cases (one at dose level 1 and four at dose level 2).
Overall OR rate was 16.7%, median survival was 22 weeks,
and median PFS was 17 weeks (Table 2 and Figure 2). There
were two toxic deaths, because of acute pneumonitis, both at
dose level 2. Grade 4 nausea and vomiting was reported in
one patient (Table 3).
Gemcitabine  Carboplatin Arm
This arm was stopped after 26 patients, because of inves-
tigators decision, not for statistical rules, when required levels of
posterior probabilities were not yet attained (Figure 3). At that
time, 22 patients had been treated at dose level 1 and four
patients at dose level 2, while escalating to dose level 3 was
never warranted by the design. There were 16 ORs (14 at
dose level 1 and 2 at dose level 2), while unacceptable
toxicity occurred in 6 cases (3 each at dose levels 1 and 2).
Overall OR rate was 61.5%, median survival was 37 weeks,
and median PFS was 25 weeks (Table 2 and Figure 2). There
were two toxic deaths, one at dose level 1, due to heart failure
with atrial fibrillation and the other one at dose level 2, due to
gastric ulcer. Grade 4 toxicity was reported in two cases for
neutropenia and in one case each for anemia and febrile
neutropenia (Table 3).
Prognostic Analysis
The results of prognostic analysis are reported in Table
4. At multivariate analysis stratified by treatment arm, PS 2
and brain metastases were independently predictive of prog-
nosis. Separate analyses were done adding to the model
IADL, ADL, and QoL score; each of these covariates reduced
the sample of patients entered into the model because of
missing data. However, none of these variables showed
independent prognostic value.
DISCUSSION
The G-STEP study evaluated the feasibility and the
activity of four Gem-containing regimens in the first-line
treatment of elderly patients with advanced SCLC: the com-
binations of Gem with either Vin, Eto, and Cis were consid-
ered not sufficiently active according to the statistical design.
On the contrary, the combination of Gem with Car, at the
lowest explored dose (AUC 3.5), showed an OR rate higher
than the threshold required to define the treatment as worthy
of further investigation; in addition, toxicity was acceptable.
However, this arm was closed not following design rules but
because of a progressive decline of the interest in the study;
as a consequence, we did not test the whole spectrum of
planned doses and cannot argue about which is the optimal
FIGURE 3. Updating of posterior probabilities that treat-
ment was not sufficiently active (green continuous line) or
too toxic (red dashed line) after each cohort of two patients
for GemEto (top), GemCis (middle), and GemCar (bottom)
arms. A posterior probability threshold of 0.90 was chosen
for both activity and toxicity. In the upper part of each
panel, the dose level of each cohort is reported.
Journal of Thoracic Oncology • Volume 7, Number 1, January 2012 The G-Step Trial
Copyright © 2011 by the International Association for the Study of Lung Cancer 239
one. Lack of interest was probably caused by the knowledge
over time of the negative outcomes in the other arms.
SCLC in elderly patients is an increasingly common
problem, as a result of longer life expectancy of the general
population: approximately 32% of newly diagnosed SCLC
cases occur in patients older than 70 years, whereas approx-
imately 10% are diagnosed in patients older than 80 years.32
Unfortunately, much of the currently available data come
from retrospective analyses of trials without an age limit.
These data should be interpreted cautiously due to the risk of
selection bias. However, such studies demonstrated greater
toxicity with platinum-based chemotherapy in the elderly.12,33
Elderly patients have more comorbidity and may tolerate
aggressive chemotherapy less well than younger patients.
Therefore, the combination of platinum compounds with Eto
is not always safe in clinical practice to treat elderly patients,
although the prophylactic use of growth factors can reduce
the occurrence of febrile neutropenia and allow delivering
full-dose chemotherapy.34
Several studies evaluated the role of single agent che-
motherapy; however, two randomized trials demonstrated the
superiority of combination regimens, even in patients with
poor PS.35,36 Empirical dose reduction is another option in
elderly patients: once again, retrospective analyses showed
that treatment with optimal doses was the best choice in terms
of response rate and survival, although resulted in consider-
able toxicity.12 Few prospective trials confirmed that the
combination of Car and Eto has not only a reasonable activity
but also an increased toxicity in the elderly.37–40 Platinum-
free regimens showed a good tolerability profile, but only
modest activity.41,42 Therefore, there is a need for prospec-
tive, elderly-specific trials. Despite its limitations, our study
is among the largest prospective studies evaluating the activ-
ity of new regimens in this setting. The delay in publication
of data was not related to study results or perspectives but to
the high number of commitments of the study group.
Our results suggest that among four Gem-containing
doublets, only GemCar seems promising for elderly patients
with extended SCLC. These findings are also consistent with
the results of a randomized study conducted in patients with
poor prognosis SCLC, showing that such combination was as
effective as Cis and Eto, with a more favorable toxicity
profile.43 Further trials including this schedule compared with
standard approaches are warranted.
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